Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Peanut Allergic Subjects
Interventions
Peanut Oral Immunotherapy (POIT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 16 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Conditions
Peanut Allergy, Milk Allergy, Egg Allergy
Interventions
Oral food challenge
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
3 Years to 21 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Ig-E Mediated Food Allergy
Interventions
RPT904, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
12 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intervention to Reduce Early (Peanut) Allergy in Children

NCT04604431
Conditions
Food Allergy Peanut, Food Allergy in Infants
Interventions
iREACH CDS Tool
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Months and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
30
States / cities
Arlington Heights, Illinois • Bloomington, Illinois • Chicago, Illinois + 16 more
Completed Phase 2 Interventional Results available

Oral Immunotherapy (OIT) for Peanut Allergy

NCT00815035
Conditions
Peanut Hypersensitivity
Interventions
Peanut OIT, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
49
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
Conditions
Peanut Allergy
Interventions
HAL-MPE1, HAL-MPE1 placebo
Biological · Drug
Lead sponsor
HAL Allergy
Industry
Eligibility
5 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 3 more
Conditions
Peanut Allergy
Interventions
Dupilumab, Placebo matching dupilumab, AR101
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Terminated Phase 1Phase 2 Interventional

Open-label Extension Study of ADP101

NCT05243719
Conditions
Food Allergy
Interventions
ADP101
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 57 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Conditions
Allergy, Peanut
Interventions
ligelizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 55 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more
Conditions
Peanut Allergy
Interventions
Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Not yet recruiting Phase 2 Interventional

UNC Cashew Sublingual Immunotherapy

NCT07170540
Conditions
Cashew Nut Allergy, Tree Nut Allergies
Interventions
Cashew sublingual immunotherapy, Placebo sublingual immunotherapy
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions
PVX-108, Placebo
Biological
Lead sponsor
Aravax Pty Ltd
Industry
Eligibility
4 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more
Conditions
Food Allergy, Peanut Allergy
Interventions
Peanut Protein, Continued peanut avoidance
Biological · Other
Lead sponsor
Scott Sicherer
Other
Eligibility
4 Years to 14 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Peanut Allergy
Interventions
Dose A, Dose B, Dose C, Dose D, Dose E, Placebo
Combination Product
Lead sponsor
Moonlight Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Overland Park, Kansas + 2 more
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies

NCT02192866
Conditions
Peanut Allergies, Tree Nut Allergies, Other Food Allergies
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2030
U.S. locations
1
States / cities
Denver, Colorado
Completed Phase 1Phase 2 Interventional Results available

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753
Conditions
Tree Nut Allergy
Interventions
Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Recruiting Phase 1Phase 2 Interventional

VE416 for Treatment of Food Allergy

NCT03936998
Conditions
Peanut Allergy
Interventions
Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT, Placebo plus placebo with PNOIT
Combination Product
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Peanut Allergy
Interventions
Peanut SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
4 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions
Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children

NCT01867671
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 48 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more
Terminated No phase listed Observational Accepts healthy volunteers

Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

NCT01212016
Conditions
Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland